Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade

Sneha Berry(Johns Hopkins University), Nicolás A. Giraldo(Johns Hopkins University), Benjamin Green(Johns Hopkins University), Tricia R. Cottrell(Johns Hopkins University), Julie E. Stein(Johns Hopkins University), Elizabeth L. Engle(Johns Hopkins University), Haiying Xu(Johns Hopkins University), Aleksandra Ogurtsova(Johns Hopkins University), Charles A. Roberts(Johns Hopkins University), Daphne Wang(Johns Hopkins University), Peter Nguyen(Johns Hopkins University), Qingfeng Zhu(Johns Hopkins University), Sigfredo Soto-Diaz(Johns Hopkins University), Jose Loyola(Johns Hopkins University), Inbal Sander(Johns Hopkins University), Pok Fai Wong(Yale University), Shlomit Jessel(Yale University), Joshua Doyle(Johns Hopkins University), Danielle Signer(Johns Hopkins University), Richard Wilton(Johns Hopkins University), J. Roskes(Johns Hopkins University), Margaret Eminizer(Johns Hopkins University), Seyoun Park(Johns Hopkins University), Joel Sunshine(Johns Hopkins University), Elizabeth M. Jaffee(Johns Hopkins University), Alexander S. Baras(Johns Hopkins University), Angelo M. De Marzo(Johns Hopkins University), Suzanne L. Topalian(Johns Hopkins University), Harriet M. Kluger(Yale University), Leslie Cope(Johns Hopkins University), Evan J. Lipson(Johns Hopkins University), Ludmila Danilova(Johns Hopkins University), Robert A. Anders(Johns Hopkins University), David L. Rimm(Yale University), Drew M. Pardoll(Johns Hopkins University), Alexander S. Szalay(Johns Hopkins University), Janis M. Taube(Johns Hopkins University)
Science
June 10, 2021
10.1126/science.aba2609
Cited by 202Open Access
Full Text

Abstract

Astronomy accelerates tumor imaging Immunohistochemical stains for individual markers revolutionized diagnostic pathology decades ago but cannot capture enough information to accurately predict response to immunotherapy. Newer multiplex immunofluorescent technologies provide the potential to visualize the expression patterns of many functionally relevant molecules but present numerous challenges in accurate image analysis and data handling, particularly over large tumor areas. Drawing from the field of astronomy, in which petabytes of imaging data are routinely analyzed across a wide spectral range, Berry et al. developed a platform for multispectral imaging of whole-tumor sections with high-fidelity single-cell resolution. The resultant AstroPath platform was used to develop a multiplex immunofluorescent assay highly predictive of responses and outcomes for melanoma patients receiving immunotherapy. Science , aba2609, this issue p. eaba2609

Related Papers

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Andreas D. Hartkopf, Florin‐Andrei Taran, Markus Wallwiener et al.|Breast Care|2016|30.9k
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll|Nature reviews. Cancer|2012|13.7k
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Naiyer A. Rizvi, Matthew D. Hellmann, Alexandra Snyder et al.|Science|2015|7.9k
Elements of cancer immunity and the cancer–immune set point
Daniel S. Chen, Ira Mellman|Nature|2017|5.3k
The immune contexture in human tumours: impact on clinical outcome
Wolf H. Fridman, Franck Pagès, Catherine Sautès‐Fridman et al.|Nature reviews. Cancer|2012|4.9k